Publicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (36)

2024

  1. Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC)

    Actas Dermo-Sifiliograficas

2023

  1. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

    European Journal of Haematology, Vol. 111, Núm. 3, pp. 485-490

  2. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells

    Frontiers in Molecular Biosciences, Vol. 10

2022

  1. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice

    International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392

  2. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain

    Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, Vol. 38, Núm. 3, pp. 252-260

2021

  1. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group

    Transplant Infectious Disease, Vol. 23, Núm. 4

  2. Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment

    Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1281-1290

  3. Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group

    American Journal of Transplantation, Vol. 21, Núm. 1, pp. 258-271

  4. European Surveillance System on Contact Allergies (ESSCA): Characteristics of patients patch tested and diagnosed with irritant contact dermatitis

    Contact Dermatitis, Vol. 85, Núm. 2, pp. 186-197

2020

  1. Efficiency in patch testing: the number needed to test to get one relevant result as a new approach in the evaluation of baseline series

    British Journal of Dermatology

  2. Incidence of upper tract urothelial carcinoma in Spain

    Actas Urologicas Espanolas, Vol. 44, Núm. 7, pp. 512-518

  3. Is p-Phenylenediamine Still a Prevalent Contact Allergen in Spain?

    Actas Dermo-Sifiliograficas, Vol. 111, Núm. 1, pp. 47-52

  4. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 3, pp. 203-213

  5. Recommendations of the Working Groups from the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) for the management of adult critically ill patients in the coronavirus disease (COVID-19)

    Medicina Intensiva, Vol. 44, Núm. 6, pp. 371-388

  6. The role of neuroinflammation in the pathogenesis of glaucoma neurodegeneration

    Progress in Brain Research (Elsevier B.V.), pp. 99-124

  7. Trend of relevant contact allergens of the feet in Spain over a period of 10 years

    Contact Dermatitis, Vol. 82, Núm. 4, pp. 211-217

2019

  1. European Surveillance System on Contact Allergies (ESSCA): Contact allergies in relation to body sites in patients with allergic contact dermatitis

    Contact Dermatitis, Vol. 80, Núm. 5, pp. 263-272

  2. Is p-Phenylenediamine Still a Prevalent Contact Allergen in Spain?

    Actas Dermo-Sifiliograficas

2018

  1. Are the Spanish baseline series markers sufficient to detect contact allergy to corticosteroids in Spain? A GEIDAC prospective study

    Contact Dermatitis, Vol. 78, Núm. 1, pp. 76-82

  2. Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation

    Seminars in Hematology, Vol. 55, Núm. 4, pp. 189-196